Abiomed Impella 2.5 and 5.0:
This article was originally published in Clinica
Abiomed has received Canadian approval for its Impella 2.5 and Impella 5.0 ventricular cardiac assist devices for maintaining circulatory support. The devices are inserted minimally invasively into the left ventricle, where they help pump blood in heart failure patients. The Danvers, Massachusetts company has already CE marked the Impella 2.5 for sale in Europe, and Abiomed has now completed enrolment in a pilot study of the technology in the US. The Impella 5.0, which can also be inserted surgically, is CE-marked too, and is in pilot studies in the US.
You may also be interested in...
FDA warning to "Genesis II Church of Health and Healing " wasn't its first to the organization about promoting a chlorine dioxide formulation, "Miracle Mineral Solution," as an unapproved new drug. 'Infowars' host Alex Jones also was warned about bogus COVID-19 claims.
The first major revision since 2007 notably provides a legal foundation for special approvals under a public health crisis.
Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.